Kiniksa Posts $677.6M 2025 ARCALYST Sales, Projects $900–920M in 2026
Kiniksa reported Q4 2025 net product revenue of $202.1 million and full year 2025 revenue of $677.6 million, a 62% increase year-over-year driven by ARCALYST adoption. Cash balance rose by $170.4 million to $414.1 million, with 2026 ARCALYST revenue forecast at $900–920 million.
1. 2025 Financial Performance
Kiniksa reported Q4 2025 total revenue of $202.1 million, up from $122.5 million a year earlier, and full year 2025 revenue of $677.6 million versus $423.2 million in 2024, resulting in net income of $59.0 million compared to a $43.2 million loss. The company ended 2025 with $414.1 million in cash and equivalents, up from $243.6 million.
2. 2026 Revenue Guidance and Cash Position
For 2026, Kiniksa expects ARCALYST net product revenue of $900 million to $920 million and anticipates remaining cash flow positive on an annual basis.
3. Clinical Pipeline Progress
ARCALYST adoption reached approximately 18% penetration among 14,000 multiple-recurrence patients, with over 4,150 prescribers and an average therapy duration approaching three years. KPL-387 Phase 2/3 dose-finding data are expected in the second half of 2026, and a Phase 1 trial for KPL-1161 is planned by year-end 2026.